To date, four ALK inhibitors (crizotinib, ceritinib, alectinib and brigatinib) have received approval by the FDA for treatment of ALK-rearranged NSCLC, while others such as lorlatinib have shown promising results in early clinical trials [8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.